A Phase 1, Open Label, Repeat Dose Study to Investigate the Safety and Pharmacokinetics of 4-week Daily Dosing of ALK-001 in Healthy Volunteers

Trial Profile

A Phase 1, Open Label, Repeat Dose Study to Investigate the Safety and Pharmacokinetics of 4-week Daily Dosing of ALK-001 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Feb 2015

At a glance

  • Drugs Retinol deuterated (Primary)
  • Indications Age-related macular degeneration; Retinal dystrophies; Stargardt disease
  • Focus Adverse reactions
  • Sponsors Alkeus Pharmaceuticals
  • Most Recent Events

    • 17 Feb 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 23 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top